SeaStar Medical (NASDAQ:ICU) Issues Earnings Results, Beats Estimates By $0.02 EPS

SeaStar Medical (NASDAQ:ICU) posted its earnings results on Thursday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports. SeaStar Medical had a negative net margin of 1,551.08% and a negative return on equity of 2,379.28%. The firm had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.25 million.

SeaStar Medical Price Performance

Shares of ICU stock traded down $0.08 during midday trading on Friday, hitting $0.38. The company had a trading volume of 1,908,280 shares, compared to its average volume of 795,491. SeaStar Medical has a 52-week low of $0.31 and a 52-week high of $3.07. The company’s 50 day simple moving average is $0.67 and its 200 day simple moving average is $0.82. The stock has a market cap of $12.96 million, a price-to-earnings ratio of -0.23 and a beta of -1.06.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, SeaStar Medical presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On SeaStar Medical

A hedge fund recently raised its stake in SeaStar Medical stock. XTX Topco Ltd grew its position in SeaStar Medical Holding Corporation (NASDAQ:ICU) by 395.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,983 shares of the company’s stock after acquiring an additional 48,674 shares during the period. XTX Topco Ltd owned about 0.54% of SeaStar Medical worth $26,000 at the end of the most recent quarter. 1.69% of the stock is owned by hedge funds and other institutional investors.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.